You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of CaSR nutrient therapy for childhood diarrhea

    SBC: Medosome Biotec, LLC            Topic: NICHD

    Project Abstract Acute infectious diarrhea is a worldwide problem especially among infants young children and immune compromised patients Sadly million children die each year not because of the infections causing diarrhea but due to the associated dehydration The pro absorptive Oral Rehydration Solution ORS is the only recommended oral therapy for children with acute diarrhea yet it ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Personalized dosing of dichloroacetate for the treatment of rare and common diseases

    SBC: Medosome Biotec, LLC            Topic: NICHD

    Pyruvate dehydrogenase complexPDCdeficiencyPDCDis a rare disease of mitochondrial energy failure in which the life of expectancy of affected children is severely truncatedTreatment of PDCD remains a seriousunmetchallengeThere has never been a controlled trial of any intervention for PDCDthusthere is no proven therapy for affected patientsDichloroacetateDCArepresents the first targeted therapy for ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel Probiotic Platform to Treat Necrotizing Enterocolitis

    SBC: MONON BIOVENTURES LLC            Topic: 300

    PROJECT SUMMARY Probiotics hold enormous potential for promoting human health and treating disease One major hurdle to many probiotic products is their lack of persistence in the gut Monon Bioventures MBV and their research partners at the Research Institute at Nationwide Childrenandapos s Hospital RINCH are developing a novel enhanced tunable technology called ProNextTM that allows for a ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Bayesian Inference of Spacecraft Geometry and Pose

    SBC: VISION SYSTEMS INC            Topic: AF17AT007

    Space platforms are complex dynamical systems and there are many reasons to model them from ground telescope imagery as well as from space-based sensor platforms. One key motivation is to determine the operational state and configuration of the vehicle. Key questions such as did the solar panels fail to deploy, did the object begin to tumble unexpectedly may be addressed by a sufficiently detaile ...

    STTR Phase I 2017 Department of DefenseAir Force
  5. Novel Silica-Based Organic Polymer for Ambient Ionization Mass Spectrometry

    SBC: Prosolia, Inc.            Topic: NIGMS

    DESCRIPTION provided by applicant Most samples of chemical interest are complex mixtures making the usual combination of chromatography with mass spectrometry MS a natural choice However the increased demand for chemical analysis by mass spectrometry in many areas of science makes it imperative to increase efficiency of analysis by minimizing sample workup and overall analysis time which ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Lowering the Cost of Imaging for Retinal Microvasculature in Diabetic Patients

    SBC: AEON IMAGING LLC            Topic: W

    DESCRIPTION provided by applicant Recently we found extensive remodeling of the microvasculature of the retina occurring in some diabetic patients much earlier than expected This provides the potential for novel biomarkers However the equipment is too expensive for most clinics and small practices These early retinal microvascular changes cannot be seen with routine clinical examination o ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Discovery of Oligodendrocyte Stimulators

    SBC: Medosome Biotec, LLC            Topic: 101

    DESCRIPTION provided by applicant Up to of low birth weight preterm infants manifest some form of periventricular white matter injury PWMI making it the most common form of brain injury affecting premature infants In the US infants per year are born at risk for PWMI and about children per year will develop PWMI World wide infants will be born each year at ri ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. A new generation of targeted therapeutics for the treatment of cancer

    SBC: NERX BIOSCIENCES, INC.            Topic: NCI

    DESCRIPTION provided by applicant Development of novel lung cancer therapeutics targeting the DNA damage response Abstract Lung tissue is constantly exposed to a wide variety of inhaled chemical agents While the majority of these maybe innocuous those that damage DNA have severe consequences Thus the DNA damage response DDR and DNA repair in these tissues is extremely important The vast ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Diagnosing aggressive prostate cancer by spectroscopic photoacoustic tomography

    SBC: Vibronix, Inc.            Topic: 102

    DESCRIPTION provided by applicant Prostate cancer PCa is the No killer among male cancer patients The ultimate test is based on transrectal ultrasound guided needle biopsy and histological examination of fixed prostate tissues This conventional diagnostic procedure is invasive missing cases of cancer due to small sampling volume Moreover it leads to an overtreatment of patients du ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemia

    SBC: MICROFLUIDIC INNOVATIONS, LLC            Topic: 102

    DESCRIPTION provided by applicant Kinase inhibitors created a new paradigm in chemotherapy and are a major focus of new oncology drug development The Bcr Abl inhibitor imatinib was a breakthrough drug for chronic myelogenous leukemia with overwhelming early results however at least of patients are either intolerant resistant or experience recurrence within years and individual respo ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government